J 2010

Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma

LUDWIG, Heinz, Zdeněk ADAM, Elena TOTHOVÁ, Roman HÁJEK, Boris LABAR et. al.

Basic information

Original name

Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma

Authors

LUDWIG, Heinz (40 Austria), Zdeněk ADAM (203 Czech Republic), Elena TOTHOVÁ (703 Slovakia), Roman HÁJEK (203 Czech Republic, guarantor), Boris LABAR (191 Croatia), Miklós EGYWD (348 Hungary), Ivan ŠPIČKA (203 Czech Republic), Heinz GISSLINGER (40 Austria), Johannes DRACH (40 Austria), Ingrid KUHN (40 Austria), Axel HINKE (276 Germany) and Niklas ZOJER (40 Austria)

Edition

Haematologica, Italy, Ferrata Storti Foundation, 2010, 0390-6078

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Italy

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 6.532

RIV identification code

RIV/00216224:14110/10:00045450

Organization unit

Faculty of Medicine

UT WoS

000281933200018

Keywords in English

thalidomide; multiple myeloma; thalidomide-interferon; progression free survival
Změněno: 25/11/2010 15:51, Mgr. Anna Potáčová, Ph.D.

Abstract

V originále

Thalidomide maintenance therapy after stem cell transplantation resulted in increased progression-free survival and overall survival in a few trials, but its role in non-transplant eligible patients with multiple myeloma remains unclear. This study assessed the impact of thalidomide-interferon in comparison to interferon maintenance therapy in elderly patients with multiple myeloma.

Links

LC06027, research and development project
Name: Univerzitní výzkumné centrum - Česká myelomová skupina (Acronym: LC MGUS)
Investor: Ministry of Education, Youth and Sports of the CR, University Research Centre - Czech Myeloma Group
MSM0021622434, plan (intention)
Name: Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií
Investor: Ministry of Education, Youth and Sports of the CR, From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies